Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 4, 2014, Pages

  Liu, Xiaona ^a   Chhipa, Rishi Raj ^a   Pooya, Shabnam ^a   Wortman, Matthew ^a   Yachyshin, Sara ^a   Chow, Lionel M L ^a   Kumar, Ashish ^a   Zhou, Xuan ^a   Sun, Ying ^a   Quinn, Brian ^a   McPherson, Christopher ^b   Warnick, Ronald E ^b   Kendler, Ady ^c   Giri, Shailendra ^d   Poels, Jeroen ^e   Norga, Koenraad ^f   Viollet, Benoit ^g,h,i   Grabowski, Gregory A ^a   Dasgupta, Biplab ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g INSERM   (France)

^h CNRS   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; CDC25C PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN; RAPTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GLIOMA CELL; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

GLIOMA; METABOLISM;

ANIMALS; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; GLIOBLASTOMA; HUMANS; LIPOGENESIS; METFORMIN; MICE; MICE, KNOCKOUT; PROTEIN KINASES; TOR SERINE-THREONINE KINASES;

EID: 84893361058     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311121111     Document Type: Article

References (60)

1. Shaw RJ, et al. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101(10):3329-3335.
2. Jones RG, Thompson CB (2009) Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 23(5):537-548.
3. Viollet B, et al. (2010) AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 45(4):276-295.
4. Hardie DG (2011) AMP-activated protein kinase: An energy sensor that regulates all aspects of cell function. Genes Dev 25(18):1895-1908.
5. Foretz M, Carling D, Guichard C, Ferré P, Foufelle F (1998) AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem 273(24):14767-14771.
6. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115(5):577-590.
7. Gwinn DM, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30(2):214-226.
8. Sabatini DM (2006) mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 6(9):729-734.
9. Guo D, et al. (2009) The AMPK agonist AICAR inhibits the growth of EGFRvIIIexpressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 106(31): 12932-12937.
10. Swinnen JV, et al. (2005) Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 65(6):2441-2448.
11. Tang YC, Williams BR, Siegel JJ, Amon A (2011) Identification of aneuploidy-selective antiproliferation compounds. Cell 144(4):499-512.
12. Guigas B, et al. (2007) AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Biochem J 404(3): 499-507.
13. Jones RG, et al. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18(3):283-293.
14. Rattan R, Giri S, Singh AK, Singh I (2005) 5-Aminoimidazole-4- carboxamide-1-beta-Dribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280(47):39582-39593.
15. Santidrián AF, et al. (2010) AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood 116(16):3023-3032.
16. Guigas B, et al. (2006) 5-Aminoimidazole-4-carboxamide-1-beta-D- ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes 55(4):865-874.
17. Barankiewicz J, Jimenez R, Ronlov G, Magill M, Gruber HE (1990) Alteration of purine metabolism by AICA-riboside in human B lymphoblasts. Arch Biochem Biophys 282(2): 377-385.
18. Shang J, Lehrman MA (2004) Activation of glycogen phosphorylase with 5-aminoimidazole- 4-carboxamide riboside (AICAR). Assessment of glycogen as a precursor of mannosyl residues in glycoconjugates. J Biol Chem 279(13):12076-12080.
19. Guigas B, et al. (2004) Metformin inhibits mitochondrial permeability transition and cell death: A pharmacological in vitro study. Biochem J 382(Pt 3):877-884.
20. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67(22):10804-10812.
21. Dykens JA, et al. (2008) Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 233(2):203-210.
22. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69(16):6539-6545.
23. Liu B, et al. (2011) Potent anti-proliferative effects of metformin on trastuzumabresistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 10(17):2959-2966.
24. Kalender A, et al. (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11(5):390-401.
25. Huang X, et al. (2008) Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412(2):211-221.
26. Memmott RM, et al. (2010) Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 3(9):1066-1076.
27. Shackelford DB, et al. (2013) LKB1 inactivation dictates therapeutic response of nonsmall cell lung cancer to the metabolism drug phenformin. Cancer Cell 23(2):143-158.
28. Laderoute KR, et al. (2006) 5?-AMP-activated protein kinase (AMPK) is induced by lowoxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 26(14):5336-5347.
29. Kato K, et al. (2002) Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 21(39):6082-6090.
30. Ríos M, et al. (2013) AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Res 73(8):2628-2638.
31. Bardella C, et al. (2012) Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism. Mol Cell Biol 32(15):3081-3094.
32. Liu L, et al. (2012) Deregulated MYC expression induces dependence upon AMPKrelated kinase 5. Nature 483(7391):608-612.
33. Jeon SM, Chandel NS, Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485(7400):661-665.
34. Banko MR, et al. (2011) Chemical genetic screen for AMPK?2 substrates uncovers a network of proteins involved in mitosis. Mol Cell 44(6):878-892.
35. Dasgupta B, Milbrandt J (2009) AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell 16(2): 256-270.
36. Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31(3):438-448.
37. Lee JH, et al. (2007) Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature 447(7147):1017-1020.
38. Nakano A, et al. (2010) AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. Nat Cell Biol 12(6): 583-590.
39. Bungard D, et al. (2010) Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 329(5996):1201-1205.
40. Egan DF, et al. (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331(6016):456-461.
41. Kim HS, et al. (2008) Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J Biol Chem 283(7): 3731-3742.
42. Faubert B, et al. (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17(1):113-124.
43. Sanders MJ, et al. (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282(45):32539-32548.
44. Chow LM, et al. (2011) Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19(3):305-316.
45. Jang T, et al. (2011) Calaoagan JM, Kwon E, Samuelsson S, Recht L, Laderoute KR. 50- AMP-activated protein kinase activity is elevated early during primary brain tumor development in the rat. Int J Cancer 128(9):2230-2239.
46. Dasgupta B, et al. (2012) The AMPK ?2 subunit is required for energy homeostasis during metabolic stress. Mol Cell Biol 32(14):2837-2848.
47. Savitsky PA, Finkel T (2002) Redox regulation of Cdc25C. J Biol Chem277(23):20535-20540.
48. Kim WH, et al. (2007) AICAR potentiates ROS production induced by chronic high glucose: Roles of AMPK in pancreatic beta-cell apoptosis. Cell Signal 19(4):791-805.
49. Xiao D, Johnson CS, Trump DL, Singh SV (2004) Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanateinduced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther 3(5):567-575.
50. Hsieh AC, et al. (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17(3): 249-261.
51. Sancak Y, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25(6):903-915.
52. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9(3):316-323.
53. Baba Y, et al. (2010) Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 103(7): 1025-1033.
54. Vazquez-Martin A, et al. (2009) Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKalphaThr172) in human cancer cells. Cell Cycle 8(5):788-791.
55. Mizrachy-Schwartz S, Cohen N, Klein S, Kravchenko-Balasha N, Levitzki A (2011) Upregulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation. J Biol Chem 286(17):15268-15277.
56. Neurath KM, Keough MP, Mikkelsen T, Claffey KP (2006) AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma. Glia 53(7):733-743.
57. Kuznetsov JN, Leclerc GJ, Leclerc GM, Barredo JC (2011) AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther 10(3):437-447.
58. Göransson O, et al. (2007) Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 282(45):32549-32560.
59. Kuhajda FP (2006) Fatty acid synthase and cancer: New application of an old pathway. Cancer Res 66(12):5977-5980.
60. Chou YW, et al. (2013) Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways. PLoS ONE 8(4):e61934.